NCT06650605 (CITADEL-123) is a Phase 1 clinical trial of 123I-ATT001 in Glioma Glioblastoma Multiforme, sponsored by Theragnostics Ltd.

Who is sponsoring NCT06650605?

NCT06650605 is sponsored by Theragnostics Ltd.

What drugs are being tested in NCT06650605?

Interventions in NCT06650605: 123I-ATT001.

What condition does NCT06650605 study?

NCT06650605 studies Glioma Glioblastoma Multiforme.

Is NCT06650605 still recruiting?

NCT06650605 is currently completed. Last updated 31 March 2026.

Last reviewed 2026-03-31 · How we verify

NCT06650605: CITADEL-123

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 1 Open-label Study of 123I-ATT001 in Subjects With Relapsed Glioblastoma

Completed Phase 1 Last updated 31 March 2026

What this trial tests

Phase 1 trial testing 123I-ATT001 in Glioma Glioblastoma Multiforme in 7 participants. Completed in 1 March 2026.

Timeline

4 July 2024

Primary endpoint
1 March 2026

1 March 2026

Quick facts

Lead sponsor	Theragnostics Ltd
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	7
Start date	4 July 2024
Primary completion	1 March 2026
Estimated completion	1 March 2026
Sites	2 locations across United Kingdom

Drugs / interventions tested

123I-ATT001 — full drug profile →

Conditions studied

Glioma Glioblastoma Multiforme — all drugs for Glioma Glioblastoma Multiforme →

Sponsor

Theragnostics Ltd — full company profile →

Who can join

18 and older, any sex, with Glioma Glioblastoma Multiforme. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase I open-label trial of 123I-ATT001 monotherapy and in combination with treatment therapies in subjects with relapsed glioblastoma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Glioma Glioblastoma Multiforme

Currently open trials in the same condition.

NCT06810544 — Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss · Phase 1, PHASE2 · recruiting
NCT06687681 — Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas · Phase 2 · recruiting
NCT05086497 — WBSI Guided Personalized Delivery of TTFields · NA · recruiting

Other Theragnostics Ltd trials

Trials by the same sponsor.

NCT03617588 — 68Ga-THP-PSMA PET/CT Imaging in High Risk Primary Prostate Cancer or Biochemical Recurrence of Prostate Cancer · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06650605 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Theragnostics Ltd
Last refreshed: 31 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06650605.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing